Clinical Trials · NCT03861039
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 443
- Start date
- Mar 2019
- Locations
- 34 sites, Japan
- Primary endpoint
- Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration